España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Adam Feuerstein
Gilead's Encouraging Remdesivir Data: Rapid Reaction On The Stock
BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial
Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study
BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial
Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study
What's Going On With Geron?
Neurotrope Returns After 'Failed' Alzheimer's Trial, But Has Anything Changed?
What's Going On With Geron?
Neurotrope Returns After 'Failed' Alzheimer's Trial, But Has Anything Changed?
Adam Feuerstein Cautious On Biogen Following Alzheimer's Study
Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial
Read More...
Adam Feuerstein Recent News
Alkermes Falls 20% After FDA Refusal To File Letter
Omeros Spikes 37% Amid Favorable Medicare Policy In Congressional Spending Bill
Proteostasis Tumbles 25% After Short Seller Calls Leading Drug Candidate 'A Dud'
Novavax Shares Rise 30% On Positive Data, But Risks Remain
Pain Therapeutics Shares Double On Clinical Study Data
10 Financial Twitter Names To Follow In 2018
'Horrible': JPMorgan Chase Receives Pushback On Biotech Conference Restrictions
4 Biotechs Boosted By Spark Therapeutic's FDA News
A Deep Dive Into MannKind's Big Bet On Afrezza
Selling The News In Acadia Pharmaceuticals
Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response
Zogenix's Dravet Syndrome Treatment Returns 'Strong'
Anlayst: NewLink Shares Have Doubled This Month And There's Still Room For More Upside
Street Puts Stamp Of Approval On Gilead's Kite Pharma Takeover
Puma Biotech Makes Big Breakthrough In Breast Cancer Treatment
Will TherapeuticsMD's Yuvvexy Pass The FDA Muster?
'Riding So More Jimmy's Can Ring The Bell': TheStreet's Adam Feuerstein To Bike For Jimmy Fund, Dana-Farber Cancer Institute
Neurotrope Denies Involvement In Paying For Promotional Articles
PreMarket Prep Recap For May 1: Feuerstein Breaks Down Neurotrop's Data Spin; Contrarianism Vs. Momentum Investing
Feuerstein On Neurotrope: The Study Failed And There Was Never 'A Lot Of Hope Here'
Neurotrope's Phase 2 Drug To Treat Alzheimer's Doesn't Clear Threshold For Statistical Significance
Exondys Sales, Takeover Speculation Fuel Sarepta Therapeutics
The Bull-Bear Debate In Therapeutics Rages From Research Notes To Twitter